ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1105

Paraoxonase 1 Gene Polymorphisms Concerning Dyslipidemia, Related Comorbidities, and Mortality of Hemodialysis (HD) Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Grzegorzewska, Alicja E., Poznan University of Medical Sciences, Poznan, Poland
  • Adamska, Paulina, Poznan University of Medical Sciences, Poznan, Poland
  • Ostromecka, Kamila, Poznan University of Medical Sciences, Poznan, Poland
  • Mostowska, Adrianna, Poznan University of Medical Sciences, Poznan, Poland
  • Warchol, Wojciech J., Poznan University of Medical Sciences, Poznan, Poland
  • Jagodzinski, Pawel P., Poznan University of Medical Sciences, Poznan, Poland

Paraoxonase 1 (PON1), a protein product of PON1, may prevent atherosclerosis influencing lipid metabolism and exerting antioxidant and anti-inflammatory activities. We focused on PON1 polymorphisms concerning dyslipidemia, coronary heart disease (CHD), myocardial infarction (MI), ischemic cerebral stroke (ICS), and mortality of HD patients.


HD subjects (n = 1407, men 782, CHD 542, MI 299, ICS 250) were genotyped for PON1 polymorphisms by high-resolution melting curve analysis (rs662) or predesigned TaqMan SNV Genotyping Assay (rs854560 and rs705379). Dyslipidemia was diagnosed by K/DOQI guidelines (2003). The TG/HDL-cholesterol ratio of ≥3.8 indicated atherogenic dyslipidemia. Standard diagnostic rules were applied for CHD, MI, and ICS recognition. Survival probability was evaluated by the Kaplan-Meyer method and Cox regression analyses.


The rs662 allele A (OR 1.70, 95% CI 1.07-2.70, P=0.023) and rs854560 TT vs. AA homozygosity (OR 1.59, 95% CI 1.09-2.32, P=0.017) contributed to the prevalence of atherogenic dyslipidemia. PON1 rs705379 was not associated with frequency of the TG/HDL-cholesterol ratios ≥3.8, but patients showing the TT genotype presented higher values of this ratio (3.92, 0.65–39.4) than possessors of the CC+CT genotypes (3.46, 0.44–49.7, P=0.039) or the CC genotype (3.42, 0.66–34.5, P=0.026). The T allele of PON1 rs854560 was associated with the higher prevalence of ICS (OR 1.38, 95% CI 1.02-1.85, P=0.034 together with age and diabetic nephropathy) and borderline with MI (OR 1.31, 95% CI 1.0-1.71, P=0.051 together with age, diabetic nephropathy, and male gender). The PON1 rs705379 TT genotype contributed to mortality from all cardiovascular diseases (HR 1.28, 95% CI 1.04-1.57, n=485, P=0.022), all cardiac diseases (HR 1.33, 95%CI 1.04-1.69, n=354, P=0.023), and CHD and its complications (HR 1.57, 95% CI 1.08-2.27, n=117, P=0.019).


All three tested PON1 polymorphisms correlate with atherogenic dyslipidemia in HD patients. Associations of PON1 with dyslipidemia, ICS, and cardiovascular mortality provide arguments for the consideration of PON1 as a therapeutic target in the prevention of atherosclerosis and its complications in uremic subjects.